'Nutropin' http://www.humangrowthhormones.biz/nutropin.xml/ 2008-11-20T19:01:37+01:00 text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----tercica-initiates-phase-ii-clinical-trial-with-next-generation-growth-hormone-product-for-the-treatment-of-short-stature January 22, 2008 -- BRISBANE, Calif. -- Tercica, Inc. (NASDAQ: TRCA) today announced that the Company has begun dosing the first patient in a Phase II clinical study... text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----introducing-the-brand-new-report-on-business-strategies-for-different-types-of-biogenerics December 6, 2007 -- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c76537) has announced the addition of new Decision Resources... text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----osteologix-ceo-to-present-at-eye-for-pharma-early-commercialization,-lifecycle-and-portfolio-management-congress-2007 October 24, 2007 -- October 25-26, Barcelo Sants Hotel, Barcelona SAN FRANCISCO -- Osteologix Inc. (OTCBB:OLGX) today announced that Philip J. Young, President and CEO... text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----ipsen:-somatuline®-depot-receives-marketing-approval-in-the-united-states-for-the-treatment-of-acromegaly August 31, 2007 -- Somatuline([R]) Depot Becomes the First Product Originating from Ipsen's R&D to Be Approved by the FDA and Marketed Globally(1) PARIS --... text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----ipsen's-first-half-2007-results-and-financial-objectives-for-the-full-year-2007 August 29, 2007 -- * Increased effort in Research & Development * Results in line with management expectations: full year 2007 operating margin guidance confirmed... text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----ipsen:-increlex®-receives-marketing-authorisation-in-the-european-union August 9, 2007 -- PARIS -- Regulatory News: Increlex([R]) is the First Recombinant Human Insulin-Like Growth Factor-1 Therapy Approved in Europe for Severe Primary... text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----tercica-reports-second-quarter-2007-financial-results August 2, 2007 -- --Company Increases Increlex 2007 Revenue Guidance-- BRISBANE, Calif. -- Tercica, Inc. (Nasdaq:TRCA) today announced financial results for the... text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----ipsen's-first-half-2007-sales-and-outlook-for-the-second-half-2007 August 1, 2007 -- * +7.6% growth in Group sales, +9.3% growth in volume sold * Continued growth outside the Major Western European Countries: +16.2% * Strong... text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----tercica-announces-agreement-with-genentech-for-worldwide-growth-hormone-and-igf-1-combination-product-development-and-commercialization July 10, 2007 -- Combination Products for the Potential Treatment of Short Stature and Adult Growth Hormone Deficiency Tercica May Receive up to $53 Million in... text/html http://www.humangrowthhormones.biz/human-growth-hormone/nutropin.xml/#business-wire----ipsen:-increlex®-receives-chmp-positive-opinion-for-the-treatment-of-severe-primary-igf-1-deficiency May 25, 2007 -- PARIS -- Regulatory News: Upon marketing authorization, Increlex([R] )will be commercialized in the European Union by Ipsen, Tercica's partner...